Get started
Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonalsOptionsETFsBonds
Full chart
Full chart

Compare with Regeneron Pharmaceuticals, Inc.



Key stats


Market capitalization
‪83.19 B‬ USD
Dividend yield (indicated)
0.47%
Price to earnings Ratio (TTM)
19.97
Basic EPS (TTM)
41.91 USD
Net income (FY)
‪4.50 B‬ USD
Revenue (FY)
‪14.34 B‬ USD
Shares float
‪99.09 M‬
Beta (1Y)
0.25

Latest earnings


Last report date
Jul 30, 2026
Report period
Q2 2026
EPS
14.29 USD
Revenue
‪4.29 B‬ USD
Earnings call summary

Revenue grew 17% year-over-year to $4.3B, with double-digit EPS growth and record sales for Dupixent, EYLEA HD, and Libtayo. Pipeline advances and upcoming regulatory milestones support a strong outlook, while robust cash flow enables continued R&D and shareholder returns.

Employees


Employees (FY)
‪15.41 K‬
Change (1Y)
+304+2.01%
Revenue / Employee (1Y)
‪930.75 K‬ USD
Net income / Employee (1Y)
‪292.34 K‬ USD

Details


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Leonard S. Schleifer
Website
regeneron.com
Headquarters
Tarrytown
Founded
1988
IPO date
Apr 2, 1991
ISIN
US75886F1075
CUSIP
75886F107
FIGI
BBG000C734W3
Identifiers
ISIN US75886F1075
CFI code
ESVUFR
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


6.164% YTM
Maturity dateSep 15, 2050
Coupon2.80% (Fixed)
5.027% YTM
Maturity dateSep 15, 2030
Coupon1.75% (Fixed)

See all REGN bonds 

ETFs holding the stock


VTI
Vanguard Morningstar Total Stock Market ETF
Weight0.09%
Market value‪2.04 B‬
QQQ
Invesco QQQ Trust, Series 1
Weight0.36%
Market value‪1.75 B‬
VOO
Vanguard S&P 500 ETF
Weight0.10%
Market value‪1.62 B‬
IVV
iShares Core S&P 500 ETF
Weight0.12%
Market value‪1.08 B‬
SPY
SPDR S&P 500 ETF TRUST
Weight0.12%
Market value‪976.20 M‬
VO
Vanguard Morningstar Mid-Cap ETF
Weight0.31%
Market value‪696.09 M‬
VTV
Vanguard Morningstar Value ETF
Weight0.24%
Market value‪611.53 M‬
IBB
iShares Biotechnology ETF
Weight5.98%
Market value‪595.94 M‬
XLV
State Street Health Care Select Sector SPDR ETF
Weight1.31%
Market value‪576.20 M‬
JEPI
JPMorgan Equity Premium Income ETF
Weight1.32%
Market value‪527.96 M‬
QQQM
Invesco NASDAQ 100 ETF
Weight0.36%
Market value‪371.35 M‬

Explore more ETFs 

Frequently asked questions


The current price of REGN is 794.85 USD — it has decreased by −0.44% in the past 24 hours. Watch Regeneron Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Regeneron Pharmaceuticals, Inc. stocks are traded under the ticker REGN.
REGN stock has risen by 6.73% compared to the previous week, the month change is a 20.06% rise, over the last year Regeneron Pharmaceuticals, Inc. has showed a 45.06% increase.
We've gathered analysts' opinions on Regeneron Pharmaceuticals, Inc. future price: according to them, REGN price has a max estimate of 1,030.00 USD and a min estimate of 641.00 USD. Watch REGN chart and read a more detailed Regeneron Pharmaceuticals, Inc. stock forecast: see what analysts think of Regeneron Pharmaceuticals, Inc. and suggest that you do with its stocks.
REGN reached its all-time high on Aug 27, 2024 with the price of 1,211.20 USD, and its all-time low was 3.00 USD and was reached on Dec 29, 1994. View more price dynamics on REGN chart.
See other stocks reaching their highest and lowest prices.
REGN stock is 1.76% volatile and has beta coefficient of 0.25. Track Regeneron Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Regeneron Pharmaceuticals, Inc. there?
Today Regeneron Pharmaceuticals, Inc. has the market capitalization of ‪82.06 B‬, it has increased by 6.76% over the last week.
Yes, you can track Regeneron Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Regeneron Pharmaceuticals, Inc. is going to release the next earnings report on Oct 29, 2026. Keep track of upcoming events with our Earnings Calendar.
REGN earnings for the last quarter are 14.29 USD per share, whereas the estimation was 10.16 USD resulting in a 40.69% surprise. The estimated earnings for the next quarter are 15.90 USD per share. See more details about Regeneron Pharmaceuticals, Inc. earnings.
Regeneron Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪4.29 B‬ USD, despite the estimated figure of ‪3.82 B‬ USD. In the next quarter, revenue is expected to reach ‪4.53 B‬ USD.
REGN net income for the last quarter is ‪1.30 B‬ USD, while the quarter before that showed ‪727.20 M‬ USD of net income which accounts for 0.00% change. Track more Regeneron Pharmaceuticals, Inc. financial stats to get the full picture.
Yes, REGN dividends are paid quarterly. The last dividend per share was 0.94 USD. As of today, Dividend Yield (TTM)% is 0.46%. Tracking Regeneron Pharmaceuticals, Inc. dividends might help you take more informed decisions.
Regeneron Pharmaceuticals, Inc. dividend yield was 0.46% in 2025, and payout ratio reached 8.49%. The year before the numbers were 0.00% and 0.00% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Aug 12, 2026, the company has ‪15.41 K‬ employees. See our rating of the largest employees — is Regeneron Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Regeneron Pharmaceuticals, Inc. EBITDA is ‪4.70 B‬ USD, and current EBITDA margin is 29.60%. See more stats in Regeneron Pharmaceuticals, Inc. financial statements.
Like other stocks, REGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Regeneron Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Regeneron Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Regeneron Pharmaceuticals, Inc. stock shows the buy signal. See more of Regeneron Pharmaceuticals, Inc. technicals for a more comprehensive analysis.